A Comprehensive Multiomic Biomarker Evaluation Across Two Single-arm Cohorts to Elucidate Mechanisms of Response and Resistance in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC)

Abroad (travel likely)RecruitingPHASE2

Conditions

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Contact: Study coordinator (Minge Xu) · minge.xu@uhn.ca · 416-946-4501

Study leads

Lillian Siu, MD
Principal Investigator
Princess Margaret Cancer Centre

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer

Head and Neck Squamous Cell Carcinoma · Recurrent Head and Neck Squamous Cell Carcinoma · Metastatic Head-and-neck Squamous-cell Carcinoma

Abroad (travel likely)RecruitingPHASE2

Winston-Salem, United States

A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Chongqing, China · Chengdu, China

H101 Plus TACE for r/m HNSCC

Head and Neck Squamous Cell Carcinoma · Oncolytic Virus · TACE

Abroad (travel likely)RecruitingPHASE2

Chengdu, China

Iparomlimab and Tuvonralimab in HNSCC

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE2

Shanghai, China